Key result
High serum fetuin-A levels were associated with lower all-cause mortality in patients with coronary artery disease (HR 0.57; 95% CI 0.37-0.87).
Why the study?
The association between serum fetuin-A level and the prognosis of patients with CAD remained controversial.
Does high serum fetuin-A level predict lower all-cause mortality and secondary CVD events in patients with CAD?
Meta-Analysis (n=4,256)
Does high serum fetuin-A level predict lower all-cause mortality and secondary CVD events in patients with CAD?
Hazard Ratio: 0.57 (95% CI 0.37–0.87)
High serum fetuin-A levels are associated with lower all-cause mortality in patients with coronary artery disease, suggesting a potential prognostic role.
BACKGROUND: Fetuin-A is an anti-inflammation and anti-calcification factor involved in the course of coronary artery disease (CAD). But the association between serum fetuin-A level and the prognosis of CAD patients was still controversial. To clarify the association between serum fetuin-A level and the prognosis of CAD patients, we conducted the present meta-analysis. METHODS: The included studies should be potentially relevant prospective studies published in English language before January 2019. The target population of the present meta-analysis was restricted to patients with CAD. The results of studies must report hazard ratio (HR) or Kaplan-Meier survival curve for all-cause mortality or incidence of secondary cardiovascular disease (CVD) events. The pooled HRs were analysed by the method of meta-analysis. RESULTS: A total of four prospective studies, including 4256 participants with CAD disease, were chosen to be included. The pooled HR for all-cause mortality was 0.57 (95% CI: 0.37-0.87), showing a statistically significant association between high serum fetuin-A level and low all-cause mortality in CAD patients. For the incidence of secondary CVD events, the pooled HR was 0.86 (95% CI: 0.60-1.23), indicating no statistically significant association between serum fetuin-A level and incidence of secondary CVD events in CAD patients. CONCLUSION: High serum fetuin-A level associated with lower all-cause mortality in patients with CAD. No association between serum fetuin-A level and incidence of secondary CVD events was found in patients with CAD.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2019) conducted a meta-analysis in Coronary artery disease (CAD) (n=4,256). High serum fetuin-A level vs. Low serum fetuin-A level was evaluated on All-cause mortality (HR 0.57, 95% CI 0.37-0.87). High serum fetuin-A levels were associated with lower all-cause mortality in patients with coronary artery disease (HR 0.57; 95% CI 0.37-0.87).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: